SUCLA2 (Succinate-CoA Ligase ADP-forming Subunit Beta) is a mitochondrial enzyme that catalyzes the conversion of succinyl-CoA to succinate in the citric acid cycle. Mutations in SUCLA2 cause mitochondrial DNA depletion syndrome (MTDPS), characterized by progressive encephalomyopathy and often early-onset neurodegeneration. The protein plays essential roles in mitochondrial energy metabolism and neuronal survival[1][2].
SUCLA2 encodes the beta subunit of succinyl-CoA ligase (also known as succinate-CoA synthetase), an enzyme that catalyzes the reversible reaction: [1]
Succinyl-CoA + ADP ↔ Succinate + CoA + ATP [2]
The enzyme exists as a heterodimer composed of alpha (SUCLG1) and beta (SUCLA2) subunits. SUCLA2 provides the nucleotide-binding domain and determines the ADP-forming specificity. The protein is localized to the mitochondrial matrix and is essential for citric acid cycle function and oxidative phosphorylation[1].
Succinyl-CoA ligase is a key enzyme linking the citric acid cycle to ATP production. SUCLA2 deficiency impairs mitochondrial respiration, reducing ATP generation in energy-demanding tissues including brain. Neurons are particularly vulnerable due to their high metabolic demands and limited regenerative capacity.
SUCLA2 mutations cause mitochondrial DNA depletion syndrome (MTDPS), characterized by reduced mitochondrial DNA copy number. This affects the formation of respiratory chain complexes, further compromising oxidative phosphorylation.
The enzyme participates in the succinate dehydrogenase (Complex II) shuttle and influences reactive oxygen species (ROS) production. Proper SUCLA2 function helps maintain redox balance in neurons.
Recessive mutations in SUCLA2 cause MTDPS with predominant encephalomyopathy. Clinical features include:
SUCLA2 mutations can present as Leigh syndrome, a severe neurodegenerative disorder characterized by bilateral brainstem and basal ganglia lesions. Patients show developmental regression, ataxia, and respiratory failure.
Mitochondrial dysfunction is a hallmark of Alzheimer's disease. SUCLA2 expression may be altered in AD brains, contributing to the bioenergetic deficits observed in the disease.
Given the importance of mitochondrial function in dopaminergic neurons, SUCLA2 dysregulation may contribute to PD pathogenesis. The protein interacts with pathways relevant to PD, including those controlling mitochondrial quality control.
Treatment approaches for SUCLA2-related disorders include:
Understanding SUCLA2's role in neuronal survival may inform therapies for more common neurodegenerative diseases characterized by mitochondrial dysfunction[3].
Carrozzo et al. Clinical spectrum of SUCLA2 mutations (2007). 2007. ↩︎
Pfeffer et al. Mitochondrial disease therapies (2020). 2020. ↩︎